Revelation Pharma Corporation Completes Ninth Acquisition With the Purchase of Austin Compounding (Austin, TX)

Revelation Pharma Corporation Completes Ninth Acquisition –
Purchases Austin Compounding (Austin, TX)

TAMPA, Fla., – Osceola Capital (“Osceola”), a lower middle-market private equity firm, announced today the ninth addition to the Revelation Pharma Corporation (“Revelation”) platform. Revelation purchased Austin Compounding Pharmacy located in Austin, Texas. Austin Compounding Pharmacy is a 503A compounding pharmacy that offers over 40 years of experience preparing sterile and non-sterile compounded medications for adult, children, and animal patients.

The acquisition of Austin Compounding Pharmacy demonstrates Revelation’s ongoing goal to build a national network of 503A and 503B compounding pharmacies. Compounding pharmacies prepare high-quality, tailored prescriptions to meet a specific therapeutic need, often enhancing patients’ quality of life.

The corporate team for Revelation is led by Richard Case, a healthcare M&A industry veteran, and Chairman of the Board, Jake Beckel, a pharmacist that has deep experience in the compounding space. Michelle Case, who has successfully directed 20+ grassroots start-ups, and launched an IPO, serves as Chief Operations Officer. Shawn Hodges, the former CEO and President of Innovation Compounding, is now the Chief Business Development Officer. Mitchell Bell is the Senior Vice President of 503A Pharmacies and was previously the Vice President of Operations at Innovation Compounding. Will Skinner is the Chief Financial Officer who has specialized in start-ups, alternative investment companies, and healthcare organizations. Jon Pritchett, former Pharmacy Program Director at Accreditation Commission for Health Care (ACHC), now serves as the Vice President of Quality Assurance and Regulatory Affairs.

The number of pharmaceutical collaborations in the works is gradually increasing. Even while pharmacy owners acknowledge the need for support in reacting to regulatory changes, they still wish to undertake pharmacy compounding and serve their patients’ particular healthcare requirements. Revelation’s long-term goal is to become the market leader in compounding by supporting and acquiring pharmacies while building a complete quality assurance system throughout the whole network.

About Osceola Capital Management
Osceola Capital is a Tampa-based private equity firm that invests in lower middle-market services companies, typically with EBITDA of $2 million to $10 million. Osceola has extensive experience partnering with management teams to execute buy-and-build strategies and drive long-term value creation. The Revelation Strategy Team includes Ben Moe, and Patrick Watkins. To learn more, visit www.osceola.com.

About Revelation Pharma Corporation
Revelation Pharma is a national network of 503A and 503B compounding pharmacies providing innovative and quality pharmaceutical products and services through “industry best” patient care and solutions for customers. Compounding pharmacy will drastically change in the next five years. Revelation believes that compounding pharmacies will need help and support to adjust to these changes in order to continue to serve the needs of the patient and their healthcare provider.

About Austin Compounding Pharmacy
Austin Compounding Pharmacy has been serving the Austin community since 2005. The pharmacy supports adult, child, and animal patients in a variety of therapeutic areas and is one of the area’s most trusted compounding pharmacies.

Contact
Shawn Hodges, PharmD
Chief Business Development Officer
shodges@revcustomrx.com

Change the future of compounding pharmacy with us

If you have any specific questions about what an exit/partnership opportunity looks like with Revelation, please contact partnerwithus@revpharmacorp.com

Tel : 1-855-434-6654